Carna Biosciences (Carna) researches and develops small molecule drug candidates to address unmet medical needs across several therapeutic areas including oncology, inflammatory diseases (rheumatoid arthritis), and neurodegenerative diseases (Alzheimer’s disease). The aim is to out-license its pipeline of drug candidates, including potential blockbuster drugs, to produce revenues by letting partners use its IP to commercialize certain drugs.